Bone Marrow Transplantation and Immune Deficiency

Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome -- acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.

Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.

Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.

Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.

Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte / macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.

Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.

Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6.

Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.

Faculty

Show

Michael S. Grimley, MD Member, Division of Bone Marrow Transplantation and Immune Deficiency

Michael S. Grimley, MD, has clinical research interests in the treatment of graft versus host disease (GVHD) after transplant and the use of umbilical cord blood as a stem cell source.

michael.grimley@cchmc.org

Michael B. Jordan, MD Member, Division of Bone Marrow Transplantation and Immune Deficiency

Michael B. Jordan, MD, specializes in caring for children with histiocytic disorders, primary immune deficiencies, or who are undergoing bone marrow transplantation. His laboratory focuses on understanding effector T cell function, immune regulation, and the pathogenesis of hemophagocytic lymphohistiocytosis. He is also conducting preclinical scientific studies in addition to a translational clinical trial.

513-636-7287 michael.jordan@cchmc.org

M. Christa Krupski, DO, MPH Member, Division of Bone Marrow Transplantation and Immune Deficiency

513-636-1776 christa.krupski@cchmc.org

Ashish R. Kumar, MD, PhD Director, Langerhans Cell Histiocytosis Center

Ashish R. Kumar, MD, PhD, is a pediatric hematologist/oncologist whose lab is investigating the biology childhood cancers and blood diseases. The current focus of research in the lab is on infant leukemia and LCH.
Visit the Kumar Lab.

513-803-1631 ashish.kumar@cchmc.org

High Res

Ashish R. Kumar, MD, PhD

Director, Langerhans Cell Histiocytosis Center

Director, Hematology/Oncology Fellowship Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-803-1631

Fax 513-636-3549

Email ashish.kumar@cchmc.org

Show All

Clinical & Research Interests

Show

Clinical

Childhood cancer and blood disorders; immune deficiency

Research

Leukemia biology; cancer biology

Visit the Kumar Lab.

Biography

Show

Dr. Kumar received his medical degree from L.T.M. Medical College, Mumbai, India, his PhD in anatomy and cell biology from the University of Iowa, pediatric residency training at the Mayo Clinic and fellowship in pediatric hematology / oncology / BMT at the University of Minnesota. He was appointed to the faculty of the University of Minnesota in the Department of Pediatrics where he was a member of the programs in pediatric leukemia and global pediatrics. He is currently an associate professor of pediatrics in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's within the University of Cincinnati College of Medicine. Dr. Kumar’s laboratory is engaged in researching the biology of infant leukemia. Discoveries made in his laboratory have significantly enhanced the current understanding of leukemia. Dr. Kumar is also active in education. He has delivered invited lectures and grand round presentations on various topics.

Visit the HLH Center of Excellence.

Learn more about the 700 Miles to Hope Bike Ride.

Dr. Kumar has been elected by peers for inclusion in the Best Doctors in America List.

Education and Training

Show

MD: LTM Medical College, Mumbai, India.

Residency: Mayo Clinic, Rochester, MN.

Fellowship: University of Minnesota, Minneapolis, MN.

PhD: University of Iowa, Iowa City, IA.

Certification: General Pediatrics; Pediatric Hematology/Oncology Subspecialty.

Licenses: State of Ohio; State of Minnesota.

Publications

Show

View PubMed Publications

Grants

Show

Role of MEIS1 in hematopoiesis and hematopoietic transformation. Principal Investigator. National Institutes of Health/National Heart, Lung, and Blood Institute. Jul 2012-Jun 2017.

Novel therapeutics of targeting mTOR pathway in T-cell leukemia. Co-investigator. National Institutes of Health/National Cancer Institute. Jul 2015-Jun 2017.

Rebecca A. Marsh, MD Clinical Director, Primary Immune Deficiency Program

Rebecca A. Marsh, MD, is an immunologist and bone marrow transplant physician. Her research focuses on understanding the pathogenesis of HLH in patients with XIAP deficiency, developing new diagnostic laboratory assays, and improving the outcomes of allogeneic bone marrow transplantation in patients with primary immune deficiencies.

hlh@cchmc.org

Kasiani C. Myers, MD Member, Division of Bone Marrow Transplantation and Immune Deficiency

Kasiani C. Myers, MD, is a bone marrow transplant physician focused on translational research in bone marrow failure and Fanconi anemia (FA), specifically the longitudinal evaluation of hematopoiesis in FA as a model for de novo leukemogenesis. These studies will lead to development and clinical trials of targeted therapies to preserve stem cell function through the elucidation of the steps in the pathway towards marrow failure and malignant transformation.

513-803-3218 kasiani.myers@cchmc.org

Kimberly A. Risma, MD, PhD Director, Allergy and Immunology Fellowship Program

Kimberly A. Risma, MD, PhD, is focused on the molecular and cellular bases of primary disorders of immune deficiency and dysregulation, especially as it relates to lymphocyte cytotoxicity. She studies the pathologic consequences of missense mutations in perforin identified in patients with hemophagocytic lymphohistiocytosis (HLH) and strives to develop novel therapies through gene therapy or small molecule chaperones.
Visit the Risma Lab website.

513-636-6771 kimberly.risma@cchmc.org

High Res

Kimberly A. Risma, MD, PhD

Director, Allergy and Immunology Fellowship Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-6771

Fax 513-636-5835

Email kimberly.risma@cchmc.org

Show All

Clinical & Research Interests

Show

Clinical

Immune deficiency; immune dysregulation

Research

Pathophysiology of perforin missense mutations identified in individuals with hemophagocytic lymphohistiocytosis; molecular mechanisms of primary immune deficiency and dysregulation; natural killer cell and cytotoxic T lymphocyte cytotoxicity

Visit the Risma Lab website.

Biography

Show

Kimberly Risma, MD, PhD, is an associate professor in the Division of Allergy and Immunology at Cincinnati Children’s within the University of Cincinnati College of Medicine.

Dr. Risma graduated magna cum laude with a Bachelor of Arts in chemistry from Duke University in 1990 and was elected into The Phi Beta Kappa Society. She then matriculated at Case Western Reserve University (CWRU) School of Medicine in the Medical Scientist Training Program (MSTP). In 1996, she completed a PhD in pharmacology. She was selected by the leadership of the CWRU MSTP as the recipient of the 1997 Martin Wahl Memorial Fund Award, given annually to recognize the graduating MD, PhD student who has demonstrated the highest level of independence in research and excellence in research and clinical skills. She was also elected to Alpha Omega Alpha Society in 1997.

In 1997, she enrolled in a pediatrics residency at Cincinnati Children’s Hospital Medical Center/University of Cincinnati. During the residency program, Dr. Risma was awarded the pediatric resident teaching award by the medical students. She also engaged in translational research studies related to the genetics of asthma under the mentorship of Dr. Gurjit Hershey, resulting in a first author publication as a pediatric resident.

In 2000, Dr. Risma was accepted to the Allergy and Immunology Fellowship Program at Cincinnati Children’s. In addition to her clinical training, she pursued an innovative research project under the mentorship of Dr. Janos Sumegi and Dr. Alexandra Filipovich. She proposed a mechanism to study the structural and functional impact of perforin missense mutations identified in patients with hemophagocytic lymphohistiocytosis. In 2004 she was awarded the Nezelof Prize for best scientific presentation at the international meeting of the Histiocyte Society. The culmination of her fellowship research project was published in the Journal of Clinical Investigation, 2006.

Upon completion of her fellowship in 2005, Dr. Risma was appointed as an assistant professor in the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center within the UC Department of Pediatrics. In 2006 Dr. Risma received a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. Dr. Risma is the director of the Allergy and Immunology Fellowship Program at Cincinnati Children's, having served in this leadership position since August of 2012.

Dr. Risma's research program focuses on understanding the molecular mechanisms of immunodeficiency and immune dysregulation in children, especially as it relates to disorders of lymphocyte cytotoxicity. In addition to her research, she sees patients from all around the country in consultation for primary immune deficiency, immune dysregulation, and allergic disorders.

Education and Training

Show

MD: Case Western Reserve University School of Medicine, Cleveland, OH, 1997.

PhD: Case Western Reserve University School of Medicine, Cleveland, OH, 1996.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 1997-2000.

Fellowship: Allergy / Immunology, Cincinnati Children's Hospital Medical Center.

Certification: Pediatrics, 2007; Allergy and Immunology, 2005.

Publications

Show

View PubMed Publications